Rule 144 sale of 61,200 Alkermes (NASDAQ: ALKS) shares disclosed

Rhea-AI Filing Summary

A holder of Alkermes plc ordinary shares has filed a Rule 144 notice to sell 61,200 shares. The shares are to be sold through Merrill Lynch on NASDAQ, with an approximate sale date of 02/02/2026 and an aggregate market value of $2,115,674.45.

The 61,200 ordinary shares were acquired on 02/02/2026 through the exercise of employee stock options in a broker-assisted cashless exercise. The filing notes that 165,117,509 ordinary shares were outstanding, providing context for the size of the planned sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	61200	2115674.45	165117509	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	02/02/2026	Exercise of employee stock options	Alkermes plc.			61200	02/02/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Alkermes (ALKS) disclose?

The Form 144 discloses a planned sale of 61,200 Alkermes ordinary shares. These shares are to be sold on NASDAQ through Merrill Lynch, with an aggregate market value of $2,115,674.45 and an approximate sale date of February 2, 2026.

How many Alkermes (ALKS) shares are planned to be sold under this Rule 144 notice?

The notice covers a proposed sale of 61,200 Alkermes ordinary shares. The filing lists an aggregate market value of $2,115,674.45 for these shares, with trading expected on NASDAQ, giving investors a sense of the transaction’s scale relative to daily trading activity.

How were the Alkermes (ALKS) shares in this Form 144 acquired?

The 61,200 Alkermes ordinary shares were acquired through the exercise of employee stock options. The acquisition date and the payment date are both listed as February 2, 2026, using a broker-assisted cashless exercise structure to cover the purchase price and related costs.

What is the market value of the Alkermes (ALKS) shares covered by this Form 144?

The filing states an aggregate market value of $2,115,674.45 for the 61,200 Alkermes ordinary shares. This figure reflects the total value of the shares planned for sale under Rule 144, based on the market price at the time the notice was prepared.

How does the planned Alkermes (ALKS) share sale compare to shares outstanding?

The Form 144 notes that 165,117,509 Alkermes ordinary shares were outstanding. The planned sale involves 61,200 shares, offering context on the transaction’s relative size compared with the total number of shares currently outstanding in the market.

Which broker and exchange are involved in this Alkermes (ALKS) Form 144 transaction?

The planned sale will be executed through Merrill Lynch, listed with its New York address. The shares are expected to trade on NASDAQ, indicating that the transaction will occur through a major U.S. securities exchange under standard market conditions.